阿替普酶联合丁苯酞早期治疗急性缺血性脑卒中的效果及对纤维蛋白原水平的影响

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Alteplase combined with Butylphthalide in the early treatment of acute ischemic stroke and its influence on the level of fibrinogen. Methods From October 2018 to October 2020, 136 patients with acute ischemic stroke in People′s Hospital of Jiangmen, Guangdong Province were divided into the Alteplase group (68 cases, intravenous thrombolytic therapy with Alteplase) and the combination group (68 cases, intravenous infusion of Butylphthalide Sodium Chloride Injection on the basis of Alteplase intravenous thrombolytic therapy)according to the random number table method. The neurological deficit score before and 24 hours after thrombolysis,the levels of fibrinogen before and 1 and 4 hours after thrombolysis and curative effect were compared between the two groups. Results At 24 hours after thrombolysis, the neurological deficit scores of the two groups were lower than those before thrombolysis, and the neurological deficit score of the combination group was lower than that of the Alteplase group, the differences were statistically significant (P＜0.05). The total effective rate of treatment in the combination group was higher than that in the Alteplase group, and the difference was statistically significant (P＜0.05). The fibrinogen levels of the two groups at 1 and 4 h after thrombolysis were lower than those before thrombolysis, the differences were statistically significant (P＜0.05), and the fibrinogen levels of the combined group were lower than those of the Alteplase group, the differences were statistically significant (P＜0.05). Conclusion Alteplase combined with Butylphthalide has a significant effect in the early treatment of acute ischemic stroke, which is conducive to the improvement of neurological function and can reduce the level of fibrinogen.

Key words： Acute ischemic stroke Alteplase Butylphthalide Fibrinogen

Received: 05 March 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I19/120

[1]	Powers WJ，Rabinstein AA，Ackerson T，et al.2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke：A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association[J].J Vasc Surg，2018，67（6）：1934-1939.
[7]	中华医学会神经病学分会脑血管病学组急性缺血性脑卒中.中国急性缺血性脑卒中诊治指南2010[J].中国临床医生，2011，39（3）：67-73.
[8]	卢方理，周经霞，贝宁.阿替普酶联合丁苯酞治疗急性脑梗死的效果及机制分析[J].山东医药，2020，60（2）：77-79.
[16]	刘建民.多模式血管再通在急性缺血性脑卒中治疗中的应用[J].心脑血管病防治，2020，20（1）：48-49.
[2]	Chen X，Li S，Chen W，et al.The Potential Value of D-Dimer to Fibrinogen Ratio in Diagnosis of Acute Ischemic Stroke[J].J Stroke Cerebrovasc Dis，2020，29（8）：104918.
[3]	Shi J，Shi R，Qin W，et al.Dynamic Changes in Fibrinogen and Prognosis of Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis[J].Neurotox Res，2020，38（3）：775-784.
[4]	Lu T，Xian W，Liang J，et al.Early changes in fibrinogen after administration of alteplase are associated with the shortterm efficacy of thrombolysis[J].Medicine（Baltimore），2018，97（13）：e0241.
[5]	Ospel JM，Menon BK，Demchuk AM，et al.Clinical Course of Acute Ischemic Stroke Due to Medium Vessel Occlusion With and Without Intravenous Alteplase Treatment[J].Stroke，2020，51（11）：3232-3240.
[6]	Ding Y，Gu Z，Zhai T，et al.Effect of butylphthalide on new cerebral microbleeds in patients with acute ischemic stroke[J].Medicine（Baltimore），2020，99（32）：e21594.
[9]	Siarnik P，Klobucníková K，Surda P，et al.Excessive Daytime Sleepiness in Acute Ischemic Stroke：Association With RestlessLegs Syndrome，Diabetes Mellitus，Obesity，and Sleep-Disordered Breathing[J].J Clin Sleep Med，2018，14（1）：95-100.
[10]	Duan Z，Wang H，Wang Z，et al.Neutrophil-Lymphocyte Ratio Predicts Functional and Safety Outcomes after Endovascular Treatment for Acute Ischemic Stroke[J].Cerebrovasc Dis，2018，45（5-6）：221-227.
[11]	Xiao L，Jia Y，Wang X，et al.The impact of preoperative fibrinogen-albumin ratio on mortality in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].Clin Chim Acta，2019，493：8-13.
[12]	Tao L，ShiChuan W，DeTai Z，et al.Evaluation of lipoprotein-associated phospholipase A2，serum amyloid A，and fibrinogen as diagnostic biomarkers for patients with acute cerebral infarction[J].J Clin Lab Anal，2020，34（3）：e23084.
[13]	Lee SJ，Hong JM，Lee SE，et al.Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes[J].BMC Neurol，2017，17（1）：101.
[14]	Deveci B，Gazi E.Relation Between Globulin，Fibrinogen，and Albumin With the Presence and Severity of Coronary Artery Disease[J].Angiology，2021，72（2）：174-180.
[18]	余利生，宋宏中，饶俊平.阿替普酶静脉溶栓治疗急性缺血性卒中的疗效及安全性评价[J].中国医药科学，2019，9（13）：242-244.
[20]	牛建平，田红梅，程鹤云，等.丁苯酞注射液联合阿替普酶治疗急性脑梗死的效果[J].河南医学研究，2019，28（7）：1241-1242.
[21]	李康睿，叶民.丁苯酞联合阿替普酶溶栓治疗急性脑梗死的临床效果及血清炎症因子的变化[J].山西医药杂志，2019，48（19）：2347-2349.
[15]	Chen X，Shen Y，Huang C，et al.Intravenous thrombolysis with 0.9 mg/kg alteplase for acute ischaemic stroke：a network meta-analysis of treatment delay[J].Postgrad Med J，2020，96（1141）：680-685.
[17]	Burgos AM，Saver JL.Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke：Meta-Analysis of 5 Randomized Trials[J].Stroke，2019，50（8）：2156-2162.
[19]	Wang S，Ma F，Huang LJ，et al.Dl-3-n-Butylphthalide（NBP）：A Promising Therapeutic Agent for Ischemic Stroke[J].CNS Neurol Disord Drug Targets，2018，17（5）：338-347.